光正眼科(002524) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥216,875,495.12, a decrease of 22.66% compared to the same period last year[2]. - Total operating revenue for Q3 2024 was CNY 698,778,682.45, a decrease of 15.5% compared to CNY 826,834,398.51 in the same period last year[12]. - Net profit for Q3 2024 was a loss of CNY 20,284,466.64, compared to a profit of CNY 11,915,450.24 in Q3 2023, indicating a significant decline[13]. - The total comprehensive income attributable to the parent company for Q3 2024 was -20,808,633.35 CNY, compared to 10,435,862.40 CNY in the same period last year[14]. - The basic and diluted earnings per share for Q3 2024 were both -0.04 CNY, down from 0.02 CNY in Q3 2023[14]. Profitability and Losses - The net profit attributable to shareholders was -¥22,082,574.08, representing a decline of 519.53% year-over-year[2]. - The net profit after deducting non-recurring gains and losses was -¥22,772,575.49, a decrease of 1,681.65% compared to the previous year[2]. - The company reported a credit impairment loss of CNY -1,487,525.86, compared to a gain of CNY 4,005,624.36 in the previous year, indicating a negative shift[13]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,430,256,154.46, down 7.69% from the end of the previous year[2]. - The company's total assets decreased to CNY 1,430,256,154.46 from CNY 1,549,365,088.25, a reduction of approximately 7.7%[11]. - Total liabilities decreased to CNY 1,153,873,387.81 from CNY 1,263,462,691.96, representing a decline of about 8.7%[11]. - Total current assets decreased from 316,469,018.19 to 272,688,601.09, a decline of approximately 13.8%[9]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥41,591,480.17, an increase of 36.13% compared to the same period last year[6]. - Cash inflow from operating activities totaled 734,282,831.44 CNY, a decrease from 750,829,875.28 CNY year-over-year[15]. - Cash outflow from operating activities was 692,691,351.27 CNY, compared to 720,277,775.74 CNY in the previous year[15]. - The net cash flow from operating activities increased to 41,591,480.17 CNY, up from 30,552,099.54 CNY in Q3 2023[15]. - The net cash flow from financing activities was -¥62,408,552.56, a decrease of 1,150.86% compared to the previous year[7]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 43,116[8]. - The largest shareholder, Guangzheng Investment Co., holds 24.91% of shares, totaling 129,168,708 shares[8]. - The total equity attributable to shareholders decreased by 3.65% to ¥272,931,924.04 compared to the end of the previous year[2]. - The total equity attributable to shareholders decreased to CNY 272,931,924.04 from CNY 283,257,684.81, a decline of about 3.5%[11]. Investments and Expenses - The company reported a significant increase in investment income of 1,269.95%, amounting to ¥8,303,343.84, due to gains from the disposal of non-current financial assets[6]. - Research and development expenses increased to CNY 1,877,901.94 from CNY 1,542,861.33, reflecting a growth of 21.8%[12]. - The capital reserve increased to CNY 76,629,827.09 from CNY 66,181,528.79, showing a growth of approximately 15.5%[11]. Other Financial Metrics - The weighted average return on net assets was -7.95%, a decrease of 9.81% year-over-year[2]. - The ending balance of cash and cash equivalents was 52,999,984.66 CNY, down from 73,841,446.54 CNY at the end of Q3 2023[16]. - The report for Q3 2024 was not audited[16].